The dose stays low
While Retatrutides 12 mg might seem larger than semaglutides 2.4 mg, it reflects a unique pharmacologic profile rather than sheer potency
3 Wegovy's own clinical trial data reported alopecia in about 3% of adult users compared to 1% of those on placebo, and in adolescent patients, 4% versus 0%
We've been using them safely in medicine for decades nicotine replacement, hormone replacement therapy (HRT), some pain medications, motion sickness drugs, certain heart treatments
#PharmaIndustry #Semaglutide #IndianPharma #GenericDrugs #Healthcare #PharmaGrowth #SupplyChain #Procurement Note: Image created with AI To view or add a comment, sign in 3,517 followers Explore related topics Trends in Glp-1 Treatment Options How Glp-1 Drugs Impact Economic Trends Advancements in Diabetes and Obesity Treatments Impact of Glp-1 Medications on Health Trends in Weight Loss Drug Accessibility Metabolomics for Health Insights Trends in Weight Management Solutions Innovations in Diabetes Care and Insulin Management Trends in Obesity Treatment Options Latest Strategies for Diabetes Management
The effects of GLP-1RAs on breast cancer risk Current evidence indicates that GLP-1RAs not only do not increase the risk of breast cancer but may also be associated with a reduced risk of breast cancer development [30]